VENTOLIN HFA METERED-DOSE AEROSOL

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

SALBUTAMOL (SALBUTAMOL SULFATE)

Saadav alates:

GLAXOSMITHKLINE INC

ATC kood:

R03AC02

INN (Rahvusvaheline Nimetus):

SALBUTAMOL

Annus:

100MCG

Ravimvorm:

METERED-DOSE AEROSOL

Koostis:

SALBUTAMOL (SALBUTAMOL SULFATE) 100MCG

Manustamisviis:

INHALATION

Ühikuid pakis:

200 DOSES

Retsepti tüüp:

Prescription

Terapeutiline ala:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0108887003; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2001-08-14

Toote omadused

_Page 1 of 24_
PRODUCT MONOGRAPH
PR
VENTOLIN HFA
salbutamol pressurised inhalation, suspension
Mfr. Std.
100 mcg salbutamol (as salbutamol sulfate) / metered dose
Bronchodilator
(beta
2
-adrenergic agonist)
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
www.gsk.ca
Date of Revision: March 16, 2021
Submission Control No.: 244377
© 2021 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK
group of companies.
_ _
_Page 2 of 24_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................... 3
SUMMARY PRODUCT INFORMATION
.....................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
...............................................................................................
3
WARNINGS AND PRECAUTIONS
..............................................................................
4
ADVERSE REACTIONS
................................................................................................
7
DRUG INTERACTIONS
................................................................................................
9
DOSAGE AND ADMINISTRATION
...........................................................................
10
OVERDOSAGE
............................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
.......................................................... 12
STORAGE AND STABILITY
......................................................................................
14
SPECIAL HANDLING INSTRUCTIONS
....................................................................
14
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................... 14
PART II: SCIENTIFIC INFORMATION
............................................................................
15
PHARMACEUTICAL
INFORMATION................